Abstract
Big plasma somatostatin (BPS) represents an artifact of measurement. High-molecular-weight globulins (α, β, and γ) in human plasma inhibit, in a concentration-dependent manner, the binding of radiolabeled somatostatin analogs to antibody directed against somatostatin. The magnitude of inhibition varies with antibody and plasma sample and is greatest for the α-globulin fraction. The mechanism of inhibition involves binding of plasma globulins to antibody, thereby blocking tracer-binding sites, and does not involve inhibition by somatostatin bound noncovalently to plasma proteins or tracer degradation. Thus BPS arises from a property of plasma rather than of somatostatin and so it is suggested that this mechanism may account for the presence of other "big" forms of hormones in plasma.
| Original language | English |
|---|---|
| Pages (from-to) | 243-252 |
| Number of pages | 10 |
| Journal | Analytical Biochemistry |
| Volume | 125 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published (in print/issue) - 15 Sept 1982 |
Funding
We thank the Wellcome Trust and the British Diabetic Association for financial support and Dr. S. McLachlan, Department of Medicine, University of Newcastle upon Tyne, advice.
| Funders |
|---|
| Wellcome Trust |
Fingerprint
Dive into the research topics of 'The nature of big plasma somatostatin: Implications for the measurement of somatostatin-like immunoreactivity in human plasma'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver